BREAKING - AI Drug Sells For $4 Billion

That makes it the biggest deal for an AI-designed drug in history.͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌ Dear Fellow Investor, On December 13, 2022, a Big Pharma giant quietly bought one AI-designed drug for $4 billion. That makes it the biggest deal for an AI-designed drug in history. But very few people even know about it...yet. Even leading investors in the U.S. have no idea. And they don't know that [this tiny AI-biotech]( designed the drug. But this won't stay quiet much longer. On January 9, 2023, ristol Myers Squibb signed a $2.7 billion deal to have their AI-platform develop six new drugs. On October 6, 2022, Eli Lilly signed a $425 million deal to have their AI-platform develop a new drug. These seven drugs alone could bring $28 billion to [this little-known company.]( That doesn't include deals they signed with Sanofi, Nimbus Therapeutics, Petra Pharma and others. Wall Street doesn't yet grasp how this company is quietly revolutionizing the drug discovery business... Which is why I believe this will be the biggest AI winner you never heard of. [Get the name of the stock here...while it's still a small-cap ]( "The Buck Stops Here," DISCLAIMER: This communication includes advertising material and PAID ADVERTISEMENTS provided to our customers. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc.[,]( discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. 99 Wall Street Suite 1446, New York, New York 10005, United States You may [unsubscribe]( or [change your contact details]( at any time. [Powered by:](